Dr. Chen Jianchao and Mr. Zheng Maoqiang from the Australia China Pharmaceutical Association led a team to visit three major listed pharmaceutical companies in Shantou to explore new opportunities for internationalization

Recently, the Australian Chamber of Traditional Chinese Medicine (ACMCA) and its delegation embarked on a visit to Shantou. Dr. Chen Jianchao, the President, and Zheng Maoqiang, the Honorary President, led the delegation. Honorary President Cai Mengshan, Honorary President Fu Zhenhui, and Huang Youzhi, the Director of the Chamber's Guangdong Office, attended together. They visited three local tertiary listed groups in Shantou, namely Xianle Health, Tai'enkang, and Wanqingnian, to deepen industry integration through on-site research and build a bridge for the coordinated development of traditional Chinese medicine and the big health industry in China and Australia. Thanks to Ma Guoping, Vice President of Shantou Health Industry Association, for his full assistance!

At Xianle Health (stock code: 300791), the inspection team visited its global production base and research and development center to gain a detailed understanding of the company's full chain service capabilities and global layout strategy as a leading CDMO in nutrition and health food. Dr. Chen Jianchao expressed appreciation for the achievements of Xianle Health in achieving localized production and continuously increasing overseas revenue through the acquisition of European and American companies. The two sides conducted in-depth discussions on issues such as international OEM of big health derivatives and cross-border supply chain collaboration, and reached a preliminary cooperation intention.

Entering the Tai'enkang (stock code: 301263) Industrial Park, the inspection team focused on the company's breakthroughs in innovative drug research and development and medical device fields, especially paying high attention to the clinical progress of its global first vitiligo innovative drug project. During the discussion and exchange, Zheng Hanjie, Chairman of Tai'enkang, gave a detailed introduction to the core corporate culture of "sincerity, progress, and authenticity" upheld by the company - to establish oneself with "sincerity" and adhere to the development foundation of honest management and sincere cooperation; To achieve long-term goals through 'progress', maintain an innovative attitude of continuous progress and courage to change; Practice with "truth" and uphold a professional attitude of treating others with sincerity and striving for excellence. This cultural concept is highly compatible with the industry integrity development and innovation breakthrough concept advocated by ACMCA. The members of the inspection team deeply agree with this. Both sides exchanged views on specific matters such as drug registration, academic promotion, and cross-border e-commerce channel cooperation, and clarified the follow-up docking mechanism.

At Wanqing Pharmaceutical (stock code: 301111), a 143 year old "Chinese time-honored brand" enterprise, the inspection team experienced the health and wellness services of the first full life cycle medical complex in eastern Guangdong, and listened to the company's planning introduction on the layout of the entire traditional Chinese medicine industry chain, the construction of bird's nest industry hub, and the integrated development of "traditional Chinese medicine+health and wellness+cultural tourism". Cai Mengshan, Zheng Maoqiang and other members of the Chamber of Commerce affirmed the practice of Wan Qingnian's deep cultivation of traditional Chinese medicine innovation. Both sides reached consensus on the direction of exporting medicinal and edible products, cooperation in Sino Australian health and wellness projects, and international dissemination of traditional Chinese medicine culture.

Dr. Chen Jianchao stated in his inspection summary that Australia is the first Western country to recognize the legal status of traditional Chinese medicine through legislation, and the health industry between China and Australia is highly complementary. The three major listed companies in Shantou have significant advantages in research and development innovation, production and manufacturing, and industrial chain integration, especially Tai'enkang's cultural core of "sincerity, progress, and authenticity" and corporate practice, which demonstrates the responsibility and commitment of Chinese pharmaceutical companies and is highly in line with the core mission of ACMCA to promote the internationalization of traditional Chinese medicine. The Chamber of Commerce will fully leverage its role in resource integration, promote deep cooperation between the two sides in technology research and development, market access, brand promotion, and other aspects, and make traditional Chinese medicine, a treasure of Chinese culture, shine with greater vitality overseas.

This inspection has provided an efficient platform for Shantou pharmaceutical companies to connect with the Australian and global markets. All three companies have stated that they will leverage the international resource advantages of ACMCA to accelerate the pace of product internationalization layout. In the future, both sides are expected to achieve breakthroughs in cross-border cooperation, mutual recognition of standards, cultural dissemination, and other fields, jointly writing a new chapter of mutual benefit and win-win in the Chinese medicine industry between China and Australia.